HilleVax
HLVX
HLVX was delisted on the 16th of September, 2025.
51 hedge funds and large institutions have $400M invested in HilleVax in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 13 closing their positions.
58% more capital invested
Capital invested by funds: $254M → $400M (+$146M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
0.52% more ownership
Funds ownership: 69.47% → 70% (+0.52%)
11% less funds holding
Funds holding: 57 → 51 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$6.87M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$1.03M |
| 3 |
State Street
Boston,
Massachusetts
|
+$799K |
| 4 |
DM
Deerfield Management
New York
|
+$513K |
| 5 |
BlackRock
New York
|
+$507K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.22M |
| 3 |
Two Sigma Investments
New York
|
-$1.59M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$656K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$462K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$12M | -1,101,237 | Closed |
|
|
GCM
52
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$656K | -60,000 | Closed |
|
|
53
Alyeska Investment Group
Chicago,
Illinois
| – | -$462K | -42,312 | Closed |
|
|
SGM
54
Seven Grand Managers
Bronxville,
New York
| – | -$376K | -34,386 | Closed |
|
55
Blackstone Inc
New York
| – | -$273K | -25,000 | Closed |
|
56
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$250K | -22,890 | Closed |
|
57
Squarepoint
New York
| – | -$201K | -18,368 | Closed |
|
58
Millennium Management
New York
| – | -$185K | -16,949 | Closed |
|
|
CCM
59
CAAS Capital Management
New York
| – | -$164K | -15,000 | Closed |
|
60
Point72 Asset Management
Stamford,
Connecticut
| – | -$164K | -15,000 | Closed |
|
|
BFM
61
Boothbay Fund Management
New York
| – | -$114K | -10,449 | Closed |
|
|
PHK
62
Point72 Hong Kong
Hong Kong
| – | -$76K | -6,950 | Closed |
|
|
CSS
63
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$9K | -800 | Closed |
|
64
UBS Group
Zurich,
Switzerland
| – | -$8.04K | -553 | -97% |
|
HLVX Hedge Fund Activity: Q3 2022 in Review
51 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in HilleVax (HLVX) for Q3 2022, worth a combined $400M — up 58% from $254M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HLVX and 7 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was Frazier Life Sciences Management, adding an estimated $6.87M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $12M sold.
- 51 institutional investors held HilleVax (HLVX) as of Q3 2022, down from 57 in Q2 2022.
- Funds reported $400M of HilleVax stock for Q3 2022, up 58% quarter-over-quarter.
- 7 funds opened new HilleVax positions in Q3 2022 and 13 closed out, a net change of -6 holders.
- The largest HilleVax buyer in Q3 2022 was Frazier Life Sciences Management, an estimated $6.87M added.
- The largest HilleVax seller in Q3 2022 was T. Rowe Price Associates, an estimated $12M sold.
Based on aggregated 13F filings for Q3 2022.